Balancing Act: Orphan Drug Makers Slash Prices In China As New Mechanism Allures
Executive Summary
From Biogen to Takeda, multinationals have been cutting prices in China in a bid to seize the emerging market for rare disease treatments, as Beijing strives to expand market access.
You may also be interested in...
Henlius Delivers On Innovation Agenda In 2021
Henlius has focused its efforts on becoming a fully-fledged biopharmaceutical company during 2021, moving away from its roots as a biosimilar drug company.
Latest Chinese Drug Coverage Comes With Steep Price Cuts, Caveats
November negotiations in China over the prices of 67 new drugs have resulted in record price cuts, averaging around 62% overall and 65% for anti-tumor products. But the sting is alleviated by the prospect of substantial volume increases.
China's Ongoing 'COVID Zero' Policies To Prompt More Domestic Deals?
China biotechs appear increasingly interested in partnering with domestic counterparts amid signs the Chinese government's restrictive "COVID Zero" policies are likely to stay until well into 2023.